English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Investigation into the psychotropic efficacy of the omega-3 fatty acids (n-3 FAs) has grown tremendously in the past decade and a half. Since the publication of Stoll et al’s1 study of n-3 for treatment of bipolar disorder, many clinical trials, in adults and children, have examined the n-3s in unipolar major depressive disorder (MDD), postpartum depression, bipolar disorder, attention deficit disorder (ADD), psychotic disorders, obsessive-compulsive disorder (OCD), and borderline personality disorder2–5. Psychiatric clinical trials of n-3 FAs in mood disorders now number in the thirties, and various metaanalyses and systematic reviews have generally, but not unequivocally, suggested benefit2,6–16. These efficacy findings are consistent with what is being learned about antidepressants in general, with the growing availability of unpublished studies and databases17, but interpreting the n-3 data is complicated by several factors:

The Impact of Omega-3 Fatty Acids on Depressive Disorders and Suicidality: Can We Reconcile 2 Studies With Seemingly Contradictory Results?